Pink Cheetah, TQL fight it out as transparency rule awaited
Oral arguments were heard last week in the broker transparency case of Pink Cheetah vs. TQL. The post Pink Cheetah, TQL fight it out as transparency rule await…
Name
Oral
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 13in the latest 23
Mood and coverage · last 7 days
Market chart- Oral · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on Oral
Newest firstGeopolitics
Could Icotyde Become Johnson & Johnson's Next Blockbuster in China?
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision give…
Healthcare
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonr…
Healthcare
FDA signs off on Merck's cholesterol-lowering pill - the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes ele…
Healthcare
AstraZeneca Pays $600M for Oral Pill That Beat Chemo in Rare Lung Cancer
Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to beat chemotherapy in a Phase III tri…
Healthcare
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
Kailera's in-licensed oral weight loss drug is currently in a global Phase II study for obesity.
Healthcare
Oral Ozempic and Wegovy pills now available for same-day delivery on Amazon
"This has been the best product launch in the last decade that we have seen."
Healthcare
US approves new oral weight-loss pill developed by Eli Lilly
Called Foundayo, the tablet becomes the second one to receive FDA's green light after Novo Nordisk's WegovyThe US Food and Drug Administration (FDA) gave the g…
Healthcare
Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor
Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk's Wegovy oral we…
Macro
U.S. Supreme Court Hears Oral Arguments in Trump-Lisa Cook Case
Firing central bank governors may prove to be a red line.
AI
An NYU professor who hates that students' work reads like McKinsey memos held AI oral exams to 'fight fire with fire'
An NYU professor who hates that students' work reads like McKinsey memos held AI oral exams to 'fight fire with fire'
Healthcare
Novo Nordisk first out of the gate with oral weight-loss drug, and its stock jumps
Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli Lilly.
Healthcare
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, and the stock tumbles
Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer's.
Healthcare
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.
Healthcare
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Healthcare
Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works - and like a larger rival, its stock price immediately suffered.
Healthcare
Lilly's Oral GLP-1 Orforglipron Demonstrates Efficacy In Type 2 Diabetes Treatment In Phase 3 Trial
(RTTNews) - Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned…
Healthcare
This biotech's stock rockets on oral obesity-drug partnership with Wegovy parent
Novo Nordisk looks to harness Septerna's broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.
Healthcare
Why an oral surgeon became a murder suspect in girlfriend's death
Sarah Harris' mother believes Dr. James Ryan dominated every aspect of her daughter's life, brought her powerful habit-forming drugs, and is therefore responsi…
'Fascinating Case': Jonathan Turley Says Catholic School Had 'Good Day' At SCOTUS Oral Arguments
'There are cases that seem to support the school'
Healthcare
OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist
(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide f…
Healthcare
How oral health may be linked to heart and brain health
New research suggests a connection between oral bacteria and Alzheimer's disease, raising concerns for those with poor dental health. With nearly 700 species o…
Technology
Supreme Court set to hear oral arguments on challenge to TikTok ban
The Supreme Court on Friday will hear oral arguments in the case involving the future of TikTok in the U.S., which could ban the app as soon as next week.
